Genome Therapeutics Corporation - GENE- Profile

Genome Therapeutics Corporation. The Group's principal activities are to discover and develop pharmaceutical and diagnostic products. The Group concentrates the product discovery and development efforts in two principal areas, Infectious diseases caused by bacterial and fungal pathogens and human diseases believed to have a significant genetic component. The Group has nine established product development programs. Its product candidate, Ramoplanin, is in Phase III clinical trials for the prevention of bloodstream infections caused by vancomycin-resistant enterococci. Also have seven product discovery and development alliances with pharmaceutical companies Amgen, AstraZeneca, bioMerieux, Schering-Plough and Wyeth. The Group maintains an active service business, GenomeVisionTM Services, providing drug discovery services to pharmaceutical, biotechnology companies and National Human Genome Research Institute. GenomeVision Services accounted for 66% of 2002 revenues and Biopharmaceutical, 34%.